The stock climbs from the very low $5 range to $6.86 on Friday...actually it was as high as $7.08 a few days earlier in the week. Let's see what do you think causes this climb? Sales force in place selling one of two long acting neurology products: Oxtellar XR™ a novel, oral, once-daily, extended-release formulation of oxcarbazepine. SUPN received FDA approval in October 2012?
Also, SUPN is waiting for final approval from FDA for Trokendi XR™ (extended-release topiramate) Trokendi XR™, a novel, oral, extended-release, once-daily formulation of topiramate. We are waiting for June 22 of this year, less than 30 days for what is holding the FDA from giving SUPN the go ahead on this product.
From Seeking Alpha 1-16-13:
"In a subsequent announcement the "tentative" status was clarified stating "final approval may not be made effective by the FDA until the period of exclusivity protection associated with safety information regarding a specific pediatric population expires." This exclusivity pertains to younger patients between the ages of 1-24 months and expires on June 22, 2013, and although the tentative marketing approval does not pertain to that age group, the FDA is requiring that pediatric safety information be included in the Trokendi XR™ label. With final approval for marketing not occurring until mid 2013."
I'm holding my shares, once a day dosing for both of these products should be important opportunities for the medical community as well as patients needing these medications.
why on earth would AYNONE pay attention to someone who has 360 posts since May 9, 2013??? ... especially when the majority of the content exists as "sdvsdvsd" or the likes???
Can you spell looser [SIC]???